Global tuberculosis incidence has declined marginally over the past decade, and
tuberculosis remains out of control in several parts of the world including Africa and Asia …

Pretomanid, an oral nitroimidazooxazine antimycobacterial agent administered as part of the
BPaL (bedaquiline, pretomanid and linezolid) and BPaMZ (bedaquiline, pretomanid …

Background Tuberculosis is the world's leading infectious disease killer. We aimed to
identify shorter, safer drug regimens for the treatment of tuberculosis. Methods We did a …

Metabolism was once relegated to the supply of energy and biosynthetic precursors, but it
has now become clear that it is a specific mediator of nearly all physiological processes. In …

Tuberculosis is the leading infectious cause of death worldwide, with 9· 6 million cases and
1· 5 million deaths reported in 2014. WHO estimates 480 000 cases of these were multidrug …

In addition to the well-known strategies of antibiotic resistance and biofilm formation,
bacterial populations possess an additional survival strategy to endure hostile environments …

Background Multidrug-resistant (MDR) tuberculosis can be acquired through de-novo
mutation during tuberculosis treatment or through transmission from other individuals with …

Introduction: Leishmaniasis is a vector-borne neglected tropical disease which manifests as
visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucocutaneous …

Tuberculosis (TB) is the ninth cause of global death, more than any other infectious disease.
With growing drug resistance the epidemic remains and will require significant attention and …

Background Outcomes of treatment of tuberculosis patients with regimens including
pretomanid have not yet been systematically reviewed. Objectives To appraise existing …